NIB Holdings (NHF) - Upside on offer

October 8, 2024

NIB Holdings engages in the underwriting and distribution of private health, life, and living insurance to residents, international students, and visitors in Australia and New Zealand. The company operates in five segments: Australian Residents Health Insurance, International(Inbound) Health Insurance, New Zealand Insurance, nib Travel, and nib Thrive segments. It is also involved in the sale and distribution of travel and disability insurance products; and provision of health management programs. The company was founded in 1952 and is based in Newcastle, Australia.

Ord Minnett has reviewed its investment thesis on NIB and concluded the health insurer still offers attractive value, with industry data due in November and upcoming details on next year’s premium rate increases likely to reinforce our positive view on the medium-term earnings outlook.

NIB shares are pricing in more risk to the earnings outlook than we perceive, leaving the stock trading at a steep circa 30% valuation discount to the benchmark S&P/ASX 200 Index. In our view, this provides plenty of valuation support and investment appeal.

We thus reiterate our Buy recommendation, with our target price of $7.25 and FY25 DPS estimate of $0.28 implying a total return of more than 25%.

Insights that count

Discover the best opportunities to outperform the market. Our research team dig deep into the market, company and stock data to bring you insights others might overlook.

Judo Capital Holdings Limited (JDO) - – Credit where credit’s due

Judo Capital provides banking products and services for small and medium businesses in Australia.

Learn More

Metcash Limited (MTS) - Hardwearing

Metcash was founded in 1927 and operates as a wholesale distribution and marketing company in Australia, primarily in the Food, Liquor, and Hardware segments.

Learn More

ResMed Inc. (RMD) - Breathe easy

ResMed Inc. develops, manufactures, distributes, and markets medical device and cloud-based software applications targeting the management of sleep apnoea.

Learn More

Want to keep up to
date on our latest news & insights

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.